Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt.

Abstract excerpt

KRAS was long deemed undruggable until the discovery of the switch-II pocket facilitated the development of specific KRAS inhibitors. Despite their introduction into clinical practice, resistance mechanisms can limit their effectiveness. Initially, tumors rely on mutant KRAS, but as they progress, they may shift to alternative pathways, resulting in intrinsic resistance. This resistance can stem from mechanisms...

Topics

• Humans
• Drug Resistance, Neoplasm
• Proto-Oncogene Proteins p21(ras)
• Neoplasms
• Epithelial-Mesenchymal Transition
• Signal Transduction